AstraZeneca publishes updated results from US-based trial of its COVID-19 vaccine

Primary analysis demonstrated 76% efficacy at preventing symptomatic COVID-19, slightly lower than previously reported 79%, although updated results showed vaccine was consistent at preventing severe or critical disease and hospitalisation, demonstrating 100% efficacy.

Source:

PharmaTimes